Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura

Immune Thrombocytopenic Purpura Clinical Trial

— NYMC207  

Official title:

The Use of Dose Dense Rituximab for High Risk Patients With Newly Diagnosed Acute Immune Thrombocytopenic Purpura

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04323748
• Other study ID #: 14124
• Status: Recruiting
• Phase: Phase 1
• Start date: February 24, 2021
• Est. completion date: July 31, 2025

Study information

• Verified date: October 2023
• Source: New York Medical College
• Contact: Erin Morris, RN
• Phone: 714-964-5359
• Email: erin_morris[@]nymc.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if a dose dense administration of Rituximab in newly diagnosed acute immune thrombocytopenic purpura (ITP) and determine relapse rate following this treatment.

Correlative studies will be performed as outlined in the appendices.

Quality of Life will be measured using the KIT as outlined in the protocol.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: July 31, 2025
• Est. primary completion date: July 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Year to 21 Years

Eligibility

Inclusion Criteria:

• Age: Subjects must be = 1 year and = 21 years of age.

• Diagnosis: Patients must have newly diagnosed ITP and a platelet count of = 20 x 109 per Liter. Bone marrow aspirate and biopsy should be performed to rule out malignancy in the bone marrow.

• High-risk features : In addition, patients must have one of more of the following high-risk criteria:

• Age = 10 years

• Grade II-IV bleeding at diagnosis

• ANA positivity

• No history of preceding infection within 2 weeks prior to ITP diagnosis

• Performance Status: Patients must have a performance status = 50%. Use Karnofsky for patients > 16 years of age and Lansky for patients less than or equal to 16 years of age. See Appendix I for performance score.

• Prior Therapy

• Patients may not have received any treatment for ITP prior to start of therapy.

• Patients may not receive systemic steroids = 0.5 mg/kg prednisone (or equivalent) within 2 weeks prior to diagnosis.

• Concomitant Medications Restrictions:

• Steroids are only warranted as premedication prior to rituximab.

• Patients who receive thrombopoetic agonists, eltrombopag or romiplostim will be taken off protocol.

• Organ Function Requirements

• Adequate Renal Function Defined As: estimated CrCl > 60 mL/min or >30% of GFR for age based on the Schwartz formula

• Adequate Liver Function Defined As: AST and/or ALT less than 5 times the upper limit of normal, and/or direct bilirubin less than the 2 times of the upper limit of normal

Exclusion Criteria

• Patients with a history of Grade III-IV allergic reaction to rituximab

• Patients with bone marrow neoplastic infiltration

• Patients with a history of hepatitis B infection

• Pregnancy and Breast Feeding

• Female patients who are pregnant are ineligible (insert the reason: "due to risks of fetal and teratogenic adverse events as seen in animal/human studies" or "since there is yet no available information regarding human fetal or teratogenic toxicities").

• Lactating females are not eligible unless they have agreed not to breastfeed their infants.

• Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained.

Related Conditions & MeSH terms

• Immune Thrombocytopenic Purpura
• Purpura
• Purpura, Thrombocytopenic
• Purpura, Thrombocytopenic, Idiopathic

Intervention

Drug:
• rituxan
The dose dense administration of rituximab will consist of 5 doses total Days: 0, 2, 7 (± 2 days), 14 (± 2 days), and 21 (± 2 days); Dose: 375 mg/m2

Locations

Country	Name	City	State
United States	New York Medical College	Valhalla	New York

Sponsors (1)

Lead Sponsor	Collaborator
New York Medical College

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To determine the safety events: Number of participants with treatment-related Grade III or higher adverse events as assessed by CTCAE v5.0.	To determine the occurrence of any Grade = 3 non hematologic toxicity (per CTCAE v.5) which is possibly, probably, or definitely related to rituximab.	1 year
Primary	To determine the Response Rate	To quantify remission rates for high-risk patients with acute ITP treated with a dose dense administration of rituximab.	1 year